Get the Stockscreener App
55.76
0.57%
-0.315
After Hours:
55.78
0.025
+0.04%
Royalty Pharma Plc stock is traded at $55.76, with a volume of 1.86M.
It is down -0.57% in the last 24 hours and up +1.03% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$56.07
Open:
$56.09
24h Volume:
1.86M
Relative Volume:
0.52
Market Cap:
$24.73B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
29.20
EPS:
1.9093
Net Cash Flow:
$574.14M
1W Performance:
+2.70%
1M Performance:
+1.03%
6M Performance:
+44.27%
1Y Performance:
+55.37%
1-Day Range:
$55.34
$56.30
1-Week Range:
$53.59
$57.22
52-Week Range:
$34.08
$57.22
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
55.79 | 24.85B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
908.33 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
[144] Royalty Pharma plc SEC Filing - Stock Titan
Form 4 Royalty Pharma Plc For: 30 June By Investing.com - Investing.com Canada
Royalty Pharma (RPRX) director gets equity grant in lieu of cash - Stock Titan
Hsbc Holdings PLC Cuts Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Hits New 12-Month HighTime to Buy? - MarketBeat
Royalty Pharma stock hits all-time high at 56.57 USD By Investing.com - Investing.com Nigeria
Royalty Pharma stock hits all-time high at 56.57 USD - Investing.com
Royalty Pharma, plc (RPRX) Rallied on Earnings Beat - Insider Monkey
Royalty Pharma (RPRX) Stock Analysis: Evaluating Its 5.37% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Rockefeller Capital Management L.P. Purchases 81,747 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Does Royalty Pharma’s (RPRX) Index Upgrade Signal Deeper Defensive Strength In Its Business Model? - simplywall.st
Royalty Pharma plc(NasdaqGS: RPRX) added to Russell 1000 Value-Defensive Index - marketscreener.com
Enterprise value to revenue forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Trading Systems Reacting to (RPRX) Volatility - Stock Traders Daily
Royalty Pharma PLC $RPRX Shares Sold by Goodman Advisory Group LLC - MarketBeat
Enterprise value to EBITDA forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Price to earnings forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to EBITDA forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to sales forward of Royalty Pharma plc – NASDAQ:RPRX - TradingView
Enterprise value to revenue forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to sales forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Price to earnings forward of Royalty Pharma Plc Class A – SWB:RPD - TradingView
Barton Investment Management Makes New Investment in Royalty Pharma PLC $RPRX - MarketBeat
Insider Sell Alert: Marshall Urist Sells Shares of Royalty Pharm - GuruFocus
Form 4 Royalty Pharma Plc For: 25 June By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Hite sells $8.16m in shares - Investing.com UK
Royalty Pharma EVP Hite sells $8.16m in shares By Investing.com - Investing.com Australia
Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,098 Shares - MarketBeat
Royalty Pharma (RPRX) EVP Marshall Urist sells 9,098 shares under 10b5-1 plan - Stock Titan
Executive-linked fund sells 150K Royalty Pharma (RPRX) shares under 10b5-1 plan - Stock Titan
Royalty Pharma Plc Class A Actuals & Estimates (NASDAQ:RPRX) - TradingView
RPRX Forecast — Price Target — Prediction for 2027 - TradingView
Form 144 Royalty Pharma plc For: 24 June By Investing.com - Investing.com Australia
Marshall Urist sells shares at Royalty Pharma plc (NASDAQ: RPRX) - Stock Titan
Royalty Pharma - Forbes
Kirr Marbach & Co. LLC IN Acquires Shares of 237,895 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Form 144 Royalty Pharma PLC For: 23 June By Investing.com - Investing.com South Africa
Look Beyond Market Euphoria After 3 FCF ETFs Rebalanced - ETF Database
Royalty Pharma plc (RPRX) Stock Analysis: Exploring an 11.88% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Three “Forever Stocks” for the AI Age - InvestorPlace
River Road Asset Management LLC Decreases Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
ROYALTY PHARMA PLC- CL A (RPRX) Stock Chart - ChartMill
Don't Ignore The Insider Selling In Royalty Pharma - simplywall.st
Royalty Pharma PLC (RPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Royalty Pharma PLC (RPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Royalty Pharma PLC (RPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
How Royalty Pharma Plc (RPRX) Affects Rotational Strategy Timing - Stock Traders Daily
Royalty Pharma PLC (RPRX) Institutional Confidence - TradingKey
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
0.99%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):